NanoString Technologies Inc NSTG
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
NanoString Technologies Inc is a biotechnology company involved in translational research and molecular diagnostics. The product portfolio is based on a novel digital molecular barcoding technology. This technology, nCounter Analysis System, uses molecular barcodes and single-molecule imaging to distinguish and count hundreds of unique transcripts in a single reaction. Geographically, it derives maximum revenue from the Americas and also has a presence in Europe and Middle East, and the Asia Pacific. Other products and services include Analysis Solutions, GeoMx Digital Spatial Profiler, Gene Expression, Vantage 3D Assays, Sample Prep, and nCounter Consumables. The system is used for performing cancer research, biomarker validation and screening, and next-generation sequencing validation.
Seattle, WA, 98109